

AMENDMENTS TO THE CLAIMS

Please amend the claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

Please cancel claims 29, 30, 32-41 and 45-56.

1. (Currently Amended) A high-throughput assay method for rapidly determining the proliferative status of a population of primitive hematopoietic cells, the method comprising the steps of: (a) incubating a cell population comprising primitive hematopoietic cells ~~substantially free of hemoglobin~~ in a cell growth medium comprising fetal bovine serum having a concentration of between 0% and 30% and methyl cellulose having a concentration of between about 0.4% and about 0.7%, and transferrin and in an atmosphere having between about 3.5% oxygen and 7.5% oxygen; (b) contacting the cell population with a reagent capable of generating luminescence in the presence of ATP; and (c) detecting luminescence generated by the reagent contacting the cell population, the level of luminescence indicating the amount of ATP in the cell population, wherein the amount of ATP indicates the proliferative status of the primitive hematopoietic cells.
2. (Original) The method of claim 1, wherein the concentration of fetal bovine serum is between about 0% and 10%.
3. (Original) The method of claim 1, wherein the concentration of methyl cellulose is about 0.7%.
4. (Original) The method of claim 1, wherein the concentration of oxygen in the atmosphere is about 5%.
5. (Original) The method of claim 1, further comprising the step of contacting the primitive hematopoietic cell population with at least one cytokine.
6. (Original) The method of claim 5, further comprising the step of generating a cell population substantially enriched in hematopoietic stem cells.
7. (Original) The method of claim 5, further comprising the step of generating a cell population substantially enriched in at least one hematopoietic progenitor cell lineage.
8. (Original) The method of claim 1, wherein the primitive hematopoietic cells are hematopoietic stem cells.
9. (Original) The method of claim 1, wherein the primitive hematopoietic cells are hematopoietic progenitor cells.

10. (Original) The method of claim 1, wherein the population of primitive hematopoietic cells comprises hematopoietic stem cells and hematopoietic progenitor cells.
11. (Original) The method of claim 1, wherein the primitive hematopoietic cells are primary hematopoietic cells.
12. (Original) The method of claim 11, wherein the primary hematopoietic cells are isolated from an animal tissue selected from the group consisting of peripheral blood, bone marrow, umbilical cord blood, yolk sac, fetal liver and spleen.
13. (Original) The method of claim 12, wherein the animal tissue is obtained from a human.
14. (Original) The method of claim 12, wherein the animal tissue is obtained from a mammal.
15. (Original) The method of claim 14, wherein the mammal is selected from the group consisting of cow, sheep, pig, horse, goat, dog, cat, non-human primates, rodents, rabbit and hare.
16. (Original) The method of claim 14, wherein the animal tissue is selected from bone marrow, yolk sac, fetal liver and spleen.
17. (Original) The method of claim 13, wherein the animal tissue is human tissue further selected from the group consisting of peripheral blood, bone marrow, umbilical cord blood, fetal liver and spleen.
18. (Original) The method of claim 11, wherein the primary hematopoietic stem cells are isolated from peripheral blood.
19. (Original) The method of claim 1, further comprising the step of selecting a differentially distinguishable subpopulation of primitive hematopoietic cells from the population of primitive hematopoietic cells, wherein the subpopulation of cells is defined by cell surface markers thereon.
20. (Previously Presented) The method of claim 19, wherein the step of selecting a subpopulation of primitive hematopoietic cells comprises the steps of: (a) contacting the population of primitive hematopoietic cells with at least one cell surface marker indicator, wherein the at least one cell surface marker indicator is a specific ligand for a cell surface marker that differentially distinguishes a subpopulation of primitive hematopoietic cells, and whereby the at least one cell surface marker indicator binds to the cell surface marker and (b) selectively isolating the at least one subpopulation of cells binding the at least one indicator.

21. (Original) The method of claim 19, wherein the cell surface marker is selected from the group consisting of CD3, CD4, CD8, CD34, CD90 (Thy-1) antigen, CD117, CD38, CD56, CD61, CD41, glycophorin A and HLA-DR, AC133 defining a subset of CD34+ cells, CD 19, and HLA-DR.
22. (Original) The method of claim 19, wherein the cell surface marker is CD34⁺.
23. (Original) The method of claim 20, wherein the subpopulation of differentially distinguishable primitive cells is selectively isolated by magnetic bead separation.
24. (Original) The method of claim 20, wherein the subpopulation of differentially distinguishable primitive cells is selectively isolated by flow cytometry and cell sorting.
25. (Original) The method of claim 1, wherein the population of primitive hematopoietic cells comprises at least one stem cell lineage selected from the group consisting of colony-forming cell-blast (CFC-blast), high proliferative potential colony forming cell (HPP-CFC), colony-forming unit-granulocyte, erythroid, macrophage, megakaryocyte (CFU-GEMM).
26. (Original) The method of claim 1, wherein the population of primitive hematopoietic cells comprises at least one hematopoietic progenitor cell lineage selected from the group consisting of granulocyte-macrophage colony-forming cell (GM-CFC), megakaryocyte colony-forming cell (CFC-mega), macrophage colony-forming cell (M-CFC), granulocyte colony forming cell (G-CFC), burst-forming unit erythroid (BFU-E), colony-forming unit-erythroid (CFU-E), colony-forming cell-basophil (CFC-Bas), colony-forming cell-eosinophil (CFC-Eo), colony-forming cell-megakaryocyte (CFC-Mega), B cell colony-forming cell (B-CFC) and T cell colony-forming cell (T-CFC).
- 27 (Original) The method of claim 1, wherein the reagent capable of generating luminescence in the presence of ATP comprises luciferin and luciferase.
28. (Original) The method of claim 5, wherein the at least one cytokine is selected from the group consisting of erythropoietin, granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, macrophage colony stimulating factor, thrombopoietin, stem cell factor, interleukin-1, interleukin-2, interleukin-3, interleukin-6, interleukin-7, interleukin-15, Flt3L, leukemia inhibitory factor, insulin-like growth factor, and insulin.
- 29-30. (Cancelled)

31. (Original) The method of claim 5, wherein the at least one cytokine is erythropoietin, granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, stem cell factor, interleukin-3, interleukin-6, and optionally Flt3L, and wherein the at least one cytokine generates a cell population substantially enriched in hematopoietic colony-forming cell erythroid, macrophage, megakaryocyte (CFC-GEMM) stem cells.

32-41 (Cancelled)

42. (Currently Amended) The method of claim 1, further comprising the step of identifying a population of primitive hematopoietic cells suitable for transplantation into a recipient patient, whereby the population is indicated by ~~having a positive proliferative status~~ having a proliferative status a level of luminescence generated by the population, wherein the level of luminescence indicates proliferative status of the primitive hematopoietic cells, which indicates suitability of the population for transplantation into the recipient patient.

43. (Previously Presented) The method of claim 1, wherein the population of primitive hematopoietic cells comprises a target cell population, and further comprising the steps of: (i) contacting the target cell population with a test compound; and (ii) determining the ability of the test compound to modulate the proliferation, and optionally differentiation, of the target cell population.

44. (Currently Amended) The method of claim 1, wherein the population of primitive hematopoietic cells comprises a plurality of target cell populations, and further comprising the steps of: (i) contacting a first sample of the primitive hematopoietic cells with a test compound; and (ii) determining the ability of the test compound to alter the proliferation of a target cell population by comparing the proliferative status of ~~of~~ target cell population in contact with the test compound with the proliferative status of a second sample of the target population of primitive hematopoietic cells not in contact with the test compound, whereby a difference in the proliferative status of the target cell populations indicates that the test compound is capable of modulating the proliferative status of a the target cell population.

45-56. (Cancelled)

Please add the following new claims:

57. (New) The method of claim 1, wherein the transferrin is an iron-saturated transferrin.

58. (New) The method of claim 57, wherein the iron-saturated transferrin is a human or bovine iron-saturated transferrin.